April 17, 2007 

Erimos Pharmaceuticals Names Dr. Scott Mohrland as President and Chief Executive Officer

​

March 26, 2007 

Erimos Pharmaceuticals Announces Phase I/Phase II Study of Terameprocol (EM-1421) in Conjunction with New Approaches to Brain Tumor Therapy (NABTT) Consortium

​

April 4, 2006 

Triangle Science Collaboration Could Impact, Avian Flu Treatment NC State, Erimos Pharmaceuticals File Patent for Joint Efforts

​

January 24, 2006 

Erimos Pharmaceuticals Announces Phase I Study of EM-1421 Initiated at Three U.S. Sites; Intravenous Formulation to Target Tumors Unresponsive to Conventional Therapy

​

October 5, 2005

Erimos Pharmaceuticals Names Vice President, Commercial

​

August 9, 2004

Erimos Pharmaceuticals Presents Positive Safety and Preliminary Efficacy Results from a Phase I Clinical Trial of EM-1421 in Refractory Cancer Patients at the 6th International Conference on Head and Neck Cancer